Non-invasive imaging modalities such as computed tomography are often used for diagnosis and assessment of gastrointestinal (GI) disease status over the long-term. The physiology of the GI tract can be assessed with contrast agents. Here, we present common protein (bovine serum albumin, BSA) stabilized bismuth sulfide nanoparticles with robust X-ray attenuation. Under the optimal conditions, this agent can outline the anatomy of the mouse GI tract on 3D computed tomography imaging, with the real-time and non-invasive visualization of nanoparticle distribution and the GI tract. Moreover, the investigation on long-term toxicity and biodistribution of these nanoparticles after oral administration indicate their overall safety. This is a promising agent for GI visualization and disease diagnosis.
Introduction
The gastrointestinal (GI) tract is an organ system within humans and other animals, which takes in food, digests it to extract and absorb energy and nutrients, and expels the remaining waster. However, there are many diseases that can affect the gastrointestinal system, including infections, inammation and cancer. Examination of the anatomy and pathology of the GI tract is mandatory for the diagnosis of GI diseases to ensure that patients can receive appropriate treatments and have a good quality of life. Traditional endoscope imaging with histologic evaluation of tissue biopsies has been performed frequently as a reference standard.
1 Unfortunately, being time-consuming and the induction of the risk for complications heavily limit the clinical application of endoscopy. Therefore, it is necessary to develop new imaging strategies to overcome invasive procedures.
2
As a complement to traditional examination, non-invasive imaging modalities, such as ultrasound (US), X-ray computed tomography (CT), positron emission tomography (PET), as well as magnetic resonance imaging (MRI), have been used as powerful tools that provide clinicians with signicant insights into the GI disease status, treatment efficacy and patient's prognosis. [3] [4] [5] By distinguishing from the assorted imaging approaches, CT imaging is a mainstay of clinical diagnostic modality with the advantages of high resolution, no depth limitation and allowing for three-dimensional (3D) reconstruction. On the basis of the X-ray absorption coefficient rule, materials with higher density (r) or high atomic numbers (Z) tend to absorb more X-rays.
6-10 Currently, barium (Z ¼ 56) sulphate (BaSO 4 ) suspension has been routinely used as a contrast agent for X-ray contrast enhancement of GI tract in clinic. However, unknown median lethal dose and incidental false positive are the main limitations of BaSO 4 suspension as an oral CT contrast agent in the clinic. 11 Other commonly used GI contrast agents are iodine-based molecules. However, due to the limited X-ray absorption efficiency of iodine (Z ¼ 53), large doses of iodine-based contrast agents are required, which may cause serious iodine hypersensitivity reactions in patients if daily used. 12, 13 Hence, the design and synthesis of novel GI tract contrast agents with low systemic toxicity and high-efficiency imaging are of great interest and highly important.
To date, much effort has been devoted to design and fabricate novel nanomaterials as CT contrast agents, which are highly desired in attempting to achieve more complementary and accurate information of GI disease. For example, several nanosized heavy metal-based CT contrast agents, such as PEGylated W 18 O 49 nanosheets, glutathione modied PbS nanodots, lanthanum-doped BaYbF 5 up-conversional nanoparticles (NPs) and pure bismuth (Bi) NPs etc., have been successfully fabricated for the visualization of GI tract.
at least three centuries. 18, 19 Thus, bismuth-based nanomaterials may have great potential to be used as contrast agents for CT imaging in a clinical setting with high sensitivity and favorable biocompatibility. Recently, Bi 2 S 3 NPs have been employed as CT contrast agents for in vivo diagnosis arising from their high Xray attenuation capability, long residence time, low toxicity, no residues in the organism, and cost effectiveness.
20-23
Encouraged by the ideal CT imaging property of Bi 2 S 3 NPs, we have designed silica-coated bismuth sulde nanorods (Bi 2 -S 3 @SiO 2 NRs) with good biocompatibility as a CT contrast agent for visualizing GI tract of mice. 24 However, the reported Bi 2 S 3 NPs are usually synthesized through complex procedures and thus frequently encounter additional aqueous modication, limited relaxivity, and insufficient targeting capacity.
19-21,23
Thus, it is of great signicance to explore a simple yet efficient method to synthesize bismuth-based nanomaterials with highly enhanced contrast efficiency and low systemic toxicity for in vivo GI tract imaging.
Herein, we developed a simple and green method using bovine serum albumin (BSA) as a template for the preparation of BSA modied Bi 2 S 3 (BSA@Bi 2 S 3 ) NPs and then applied them as CT contrast agents of GI tract of mice. In this process, BSA could act as not only a source of sulphur but also a sacricial target to stabilize NPs either in the acidic or intestinal environment of GI tract. [25] [26] [27] [28] [29] In our study, BSA coated on the surface of Bi 2 S 3 NPs could decrease the unwanted leakage of bismuth ions and withstand the harsh conditions of the GI tract. With good biocompatibility and neglectable hemolysis, the asprepared BSA@Bi 2 S 3 NPs exhibited much signicant contrast enhancement for real-time and non-invasive visualization of in vivo GI tract via CT imaging. In addition, the results of histological analysis and biodistribution indicate that the nanoparticles are able to pass through the GI tract without inducing signicant toxicological effects. Thus, the BSA@Bi 2 S 3 NPs can be applied as a promising candidate of CT contrast agents for visualization of GI tract in vivo.
Experimental

Materials
All reagents were of analytical grade and were used as received without further purication. Bovine serum albumin (BSA, fraction V) was bought from Sangon Biotech Co., Ltd. (Shanghai, China). Bi(NO 3 ) 3 $5H 2 O was purchased from Alfa Aesar (Shanghai, China). BaSO 4 was purchased from Qingdao Dongfeng Chemical Co., Ltd. Sodium hydroxide (NaOH) was supplied by Beijing Chemical Reagent Co. China. Deionized water was obtained from a recirculating deionized water system (SHRO-plus DI, 18.2 MU cm at 25 C).
Characterization
The morphology and elements distribution of NPs were observed using eld emission transmission electron microscopes (TEM, Tecnai G 2 F20 U-TWIN) coupled with energy dispersive X-ray spectroscopy (EDS) analysis. Powder X-ray diffraction (XRD) patterns of the dried products were measured using a Japan Rigaku D/max-2500 diffractometer with Cu K a radiation (l ¼ 1.5418Å). Fourier transform infrared (FT-IR) spectra were recorded on an infrared spectrometer (iN10-iZ10, Thermo Fisher). All photographs were taken by Nikon D3100 digital camera. The contents of bismuth element in samples were measured using inductively coupled plasma mass spectrometry (ICPMS, Thermo Elemental X7, USA). 
Leaching the leakage of bismuth ions from BSA@Bi 2 S 3 NPs
To evaluate the resistance ability of the GI tract environment of BSA@Bi 2 S 3 NPs, different pH buffer solutions (2.00 and 8.00) were prepared to mimic the environment of GI system. 150 mg of BSA@Bi 2 S 3 NPs were immersed in 15 mL of various buffer solutions (with the concentration 10 mg mL À1 of BSA@Bi 2 S 3 NPs) for 2 days. Then, the solutions of BSA@Bi 2 S 3 NPs were centrifuged at 60 000 rpm for 30 min. To assess the leakage of bismuth element, the supernatants were collected for ICP-MS analysis.
In vitro CT imaging
To assess CT contrast efficiency, various concentrations of BSA@Bi 2 S 3 NPs were dissolved in the 0.5% agarose gel solution and then set in the 1.5 mL centrifuge tubes for in vitro CT signal detection. For comparison, the corresponding concentrations of BaSO 4 suspension were used as the control group. The Gamma Medica-Ideas instrument was employed to accomplish CT imaging, and the Triumph TM X-O TM CT system was further used to obtain the Hounseld unit values and CT images. The imaging parameters were as follows: effective pixel size, 80 kV, 50 mm, 270 mA; eld of view, 1024 pixels Â 1024 pixels.
In vitro toxicology
HeLa cells (human cervical cancer cells) and BGC-823 cells (human gastric carcinoma cells) were grown in 96-well culture plates with the culture mediums DMEM and RPMI 1640 supplemented with 10% FBS at 37 C under a humidied 5% CO 2 atmosphere, respectively. Cell viabilities were evaluated using the Cell Counting Kit-8 (CCK-8, Dojindo Laboratories, Shanghai, China) assay. The evaluation was performed as follows. Cells were cultured in a 96-well plate at a density of 1 Â 10 4 cells per well. The cells were washed twice with phosphate-buffered saline (PBS, pH ¼ 7.40) and incubated with different concentrations of BSA@Bi 2 S 3 NPs for 24 h. Subsequently, 10 mL of fresh CCK-8 was added into the culture medium, and the cells were incubated for an additional 1.5 h (37 C under 5% CO 2 ). Finally, the microplate reader (Thermo Scientic, MUL-TISCAN MNK3) was used to measure the absorbance of the samples at the characteristic peak of 450 nm.
In vitro hemolysis assay
To evaluate the in vitro biocompatibility, 1 mL of blood samples (obtained from mice), which were stabilized by ethylenediaminetetraacetic acid (EDTA), was added to 2 mL of PBS, and red blood cells (RBCs) were separated from serum by centrifugation at 2000 rpm for 10 min, washed several times with PBS, and then diluted into 10 mL of PBS. Then, 0.2 mL of diluted red blood cells suspension was taken out to mix with (i) 0.8 mL of PBS as a negative control, (ii) 0.8 mL of deionized water as a positive control, and (iii) 0.8 mL of BSA@Bi 2 S 3 NPs dispersions at concentrations ranging from 0 to 250 mg mL À1 .
Aerward, all the mixtures were vortexed and kept at room temperature for 4 h and then centrifuged at 12 000 rpm for 5 min. The absorbance of supernatants at 541 nm was measured by UV-vis spectroscopy. The hemolysis percent of RBCs was calculated using the following equation:
where A sample , A negative , and A positive are the absorbance of the samples, negative control, and positive control, respectively.
Animals
Male BALB/c mice (8 weeks, 18-23 g) were purchased from Beijing Vitalriver Experimental Animal Technology Co. Ltd and housed in stainless steel cages under the standard conditions with a 12 h light/dark cycle. Distilled water and sterilized food for mice were available ad libitum. All procedures used in this experiment were performed in compliance with the guidelines of institutional animal care and use committee (Institute of High Energy Physics, Beijing, China) and approved by the ethical committee of the CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety (China).
In vivo CT imaging of GI tract
In vivo CT imaging was performed on small mice X-ray CT (Gamma Medica-Ideas). 
Body weight measurements
For in vivo body weight measurements, the BALB/c mice (n ¼ 4 each time point) were orally administered with a certain volume of BSA@Bi 2 S 3 NPs solution (20 mg mL À1 ). The body weights of these mice in above two groups were recorded for 28 days.
Histology analysis using H&E staining
For histology studies, mice were sacriced 28 days aer oral administration of a certain volume of BSA@Bi 2 S 3 NPs solution (20 mg mL
À1
). Main organs including heart, spleen, liver, lung, kidney, stomach, intestine and caecum were collected. These organs were weighed, set and xed in 4% paraformaldehyde solution, processed in paraffin, sectioned and stained with H&E. The representative H&E images were analyzed with an inverted uorescence microscope (Olympus X73, Japan).
Blood hematology and biochemistry analysis
Blood samples were collected from the mice fundus artery aer oral administration of a certain volume of BSA@Bi 2 S 3 NPs solution (20 mg mL
À1
). Approximately 100 mL of the collected blood sample solution was set in the anticoagulant tub (potassium EDTA collection tube) for hematology analysis. One milliliter of the residual blood was collected from each mouse, set at room temperature for 2 h, and then centrifuged at 1500 rpm for 5 min to remove blood cells. The obtained blood plasma was used for the biochemistry test. The analyses of biochemistry and blood hematology were nished at the animal department of the Peking University medical laboratory.
Statistical analysis
All data were expressed in this article as mean result AE standard deviation (SD). All gures shown in the present work were obtained from several independent experiments with similar results. The statistical analysis was performed by using Origin 8.0 soware.
Results and discussion
The synthesis of BSA@Bi 2 S 3 NPs and characterization BSA is the most abundant plasma protein that has been widely used in bionanotechnology applications such as sensing, selfassembly, and imaging.
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Our preparation process of BSA@Bi 2 S 3 NPs is very similar to the biomineralization behavior of organisms in nature: sequestering and interacting with inorganic ions, followed by providing scaffolds for minerals formed, mostly through functional proteins. 30 Typical transmission electron microscope (TEM) image of the as-synthesized BSA@Bi 2 S 3 NPs showed a uniform size with diameter of about 1-3 nm (Fig. 1a) . X-ray diffraction (XRD), energy dispersive X-ray spectroscopy (EDS), and X-ray photoelectron spectroscopy (XPS) were conducted to investigate the chemical composition and purity of the as-prepared BSA@Bi 2 S 3 NPs. Although the X-ray diffraction peaks are poorly resolved as shown in Fig. S2 , † the general diffraction patterns are still matched with those of pure Bi 2 S 3 orthorhombic phase found in JCPDS 17-0320. EDS results conrmed that Bi and S were detected in the samples which came from Bi 2 S 3 NPs. Meanwhile, C and O probably came from both the carbon-coated copper grid and BSA protein on the surface of the NPs (Fig. 1b) . XPS was employed to identify the oxidation state and composition of BSA@Bi 2 S 3 NPs. The atomic ratio of Bi : S was approximately 2 : 2.6, close to the stoichiometric ratio of BSA@Bi 2 S 3 NPs. As shown in Fig. 1c, two respectively. Another two weak peaks at 160.1 eV and 162 eV was assigned to S 2p. 36 No peaks were detected for metallic Bi and other impurities, which indicates the high purity of the asprepared BSA@Bi 2 S 3 NPs. Fourier transform infrared (FT-IR) spectroscopy was also adopted to analyze the resulting NPs (Fig. 1d) . The bands of BSA@Bi 2 S 3 NPs are in the same regions and have the same features as those of the pure BSA. Since BSA molecules remained anchoring on the nanoparticle surface, the resulting NPs were well stable in water and biocompatible. Moreover, the result of FT-IR spectra also implied that the encapsulation of NPs in BSA molecules did not seem to affect the structure of the BSA scaffolds. Meanwhile, this also facilitates post-synthesis surface modications with other ligands. The DLS analysis indicated there was no signicant change for the size of BSA@Bi 2 S 3 NPs and they were still well dispersed in water, buffer solution (pH 2.00 and 8.00), DMEM cell medium and DMEM cell medium containing 10% FBS aer 24 h (Fig. S3 †) . The favorable colloidal stability ensures their practicability for their biomedical applications.
CT imaging in vitro
Since bismuth element has a higher photoelectric absorption coefficient than I, Ba, and Au, Bi-based NPs have alternative potentiality for use as a CT contrast agent.
37 This is clearly demonstrated from the determined Hounseld units (HU) values of BSA@Bi 2 S 3 NPs with various concentrations. As shown in Fig. 2 , the HU values linearly increased with the concentration of BSA@Bi 2 S 3 NPs, and its slope was about 51.06, which is much higher than that of BaSO 4 (21.78). The above results indicate that BSA@Bi 2 S 3 NPs can provide an equivalent contrast at a lower dose relative to clinical BaSO 4 suspension. The reduced dose in administration is highly favorable as it could signicantly minimize the side effects in patients.
Stability assessment and biocompatibility
Firstly, to assess whether the as-prepared NPs could withstand harsh acidic environment of GI tract, the pH stability of BSA@Bi 2 S 3 NPs was investigated. The leaching of Bi 3+ ions was insignicant aer 2 days incubation in simulated stomach uids (pH 2.00) and a simulated intestine uids (pH 8.00) (Fig. S4 †) . Besides, biocompatibility is an essential concern when it comes to the development of nanomaterials for biomedical application. Viabilities of two kinds of cells, including HeLa cell line (human cervical cancer cells) and BGC-823 cell line (human gastric carcinoma cells), were measured aer exposed to BSA@Bi 2 S 3 NPs. CCK assay showed that the cell viabilities associated with Hela cells and BGC 823 cells were not inuenced by BSA@Bi 2 S 3 NPs up to a concentration of 100 mg mL À1 (Fig. 3a and b) . In addition, we also investigated the inuence of BSA@Bi 2 S 3 NPs on hemolytic behavior of red blood cells (RBCs) to further evaluate their hemocompatibility, where deionized water and PBS were denoted as positive and negative controls, respectively. It is found that negligible hemolysis of RBCs is detected, indicating that BSA@Bi 2 S 3 NPs possess admirable blood compatibility (Fig. 4) . These results demonstrate the excellent stability in harsh GI tract conditions and good biocompatibility of BSA@Bi 2 S 3 NPs.
In vivo CT imaging of GI tract
Based on the above results, we then assessed the feasibility of BSA@Bi 2 S 3 NPs as a CT contrast agent to visualize the GI tract. The 3D-renderings CT images of GI tract show the process of BSA@Bi 2 S 3 NPs through the GI tract (Fig. 5) . The main organs of digestive system, including stomach, duodenum and a few loops of the small intestine, began to be bright obviously at 5 min aer oral administration of the contrast agent. Aer 30 min, the small intestine was lighted up due to the presence of much more BSA@Bi 2 S 3 NPs. More importantly, the arrangement and sequence of the small intestinal loops could be described clearly. This is particularly valuable for the detection of inammatory and neoplastic intestinal lesions, and allows accurate detection of extra-intestinal ndings. 3, 38 In contrast, the perfuse effect of BaSO 4 suspension to visualize stomach and intestine was unsatisfactory due to its innate insolubility (Fig. S5 †) . At 180 min aer the administration of BSA@Bi 2 S 3 NPs, the small intestinal empting advanced signicantly and large intestine began to be lled with NPs. Aer 1 day, almost all the BSA@Bi 2 S 3 NPs were excreted from the body and only a small amount of the NPs were in the big intestine. Except visualizing the BSA@Bi 2 S 3 NPs distribution in GI tract of mice by the 3D CT images, we also investigated the CT values (HU) of GI tract of mice aer oral administration of the NPs. The HU value of the stomach reached the maximum 1304.12 at 5 min aer oral administration of BSA@Bi 2 S 3 NPs and then gradually became weak. Meanwhile, the HU value of the intestine gradually increased and reached the maximum 1120.5 at 2 h aer the oral administration (Fig. S6a †) . In addition, the CT values of the stomach and intestine using BSA@Bi 2 S 3 NPs as contrast agent in GI tract were much higher than that of BaSO 4 suspension as contrast agent in GI tract, which was consistent with the comparison of CT images (Fig. S6b †) . The above results reveal that BSA@Bi 2 S 3 NPs have a great potential to be used for enhanced CT imaging of the GI tract.
In vivo toxicity
Safety of the nanomaterials is an essential concern when it comes to the design of them for biomedical applications.
39-43
Therefore, we then performed a series of experiments in vivo, including the body weight, histological analysis, biodistribution, blood biochemistry and hematology analysis, to ensure the safe application of BSA@Bi 2 S 3 NPs. The results in Fig. S7 † reveal that the body weights of mice with oral BSA@Bi 2 S 3 NPs decreased in the rst 5 days and then the growth rate of body weight gradually increased and became normal compared with the control group, suggesting that the BSA@Bi 2 S 3 NPs exhibited no long-term systemic effects at the given dose. Histological analysis via hematoxylin and eosinstained images further revealed that no noticeable tissue damage and adverse effect to these organs could be observed for BSA@Bi 2 S 3 NPs treated groups compared with the control group ( Fig. 6 and S8 †) at 28 day. The biodistribution results indicate that there is no signicant accumulation of BSA@Bi 2 S 3 NPs in the major organs such as heart, liver, spleen, lungs and kidney, but there is only a small quantity of BSA@Bi 2 S 3 NPs in the caecum aer 28 days (Fig. S9 †) . This may be because NPs are in direct contact with GI environment and the caecum has a physiologically complex structure, making it the target organ for the NPs. The NPs pass through the GI tract following the order: stomach, small intestine, caecum and nally the large intestine. They appear to overcome the stomach medium and target the caecum specically. This biodistribution pattern could inspire us to develop their applications further in GI nanomedicine. 44 Liver injury markers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) were also evaluated to investigate the risks of BSA@Bi 2 S 3 NPs. Although there was a slight disorder in AST at 14 day, all values of ALT and ALP were rather comparable with those of the control group. In addition, the indicators of kidney injury such as urea and creatinine were at regular intervals. These results suggest that BSA@Bi 2 S 3 NPs show no noticeable renal dysfunction induced by the NPs (Fig. 7a) . The result of hematology analysis also exhibits that the parameters of several important hematology markers in the test group appear to be nearly normal compared to the control group (Fig. 7b) . These preliminary results prove that NPs have low toxicity to mice at our tested dose. Therefore, the proposed high-performance BSA@Bi 2 S 3 NPs held high biocompatibility and low systemic toxicity in vivo, in accordance with the results from in vitro study.
Conclusion
In summary, we have fabricated a simple yet efficient method for preparation of BSA coated Bi 2 S 3 NPs. Both in vitro and in vivo studies demonstrated that the resulting BSA@Bi 2 S 3 NPs showed good biocompatibility and had the ability of withstanding the harsh environments in GI tract. Moreover, owing to their ultrahigh efficiency in absorbing X-ray, BSA@Bi 2 S 3 NPs can be applied for CT imaging of GI tract, realizing the visualization of gastrointestinal structures, such as the sequence and arrangement of the small intestinal loops. The above results suggest that BSA@Bi 2 S 3 NPs may pave an alternative way for fabrication of the CT contrast agent for direct and non-invasive visualization of GI tract with low toxicity.
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